Actively Recruiting
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Led by The First Affiliated Hospital of Xiamen University · Updated on 2025-02-19
25
Participants Needed
1
Research Sites
110 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To investigate the safety and efficacy of the ATRA combined with the KPD regimen in patients with refractory relapsed multiple myeloma.
CONDITIONS
Official Title
All-trans Retinoic Acid in Combination With a KPD Regimen for the Treatment of Refractory/Relapsed Multiple Myeloma
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Diagnosed with multiple myeloma with 10% or more monoclonal plasma cells in bone marrow confirmed by history or biopsy
- Measurable disease with specified levels of serum or urine M protein or abnormal free light chain ratio
- Diagnosed with refractory or relapsed multiple myeloma based on defined disease progression criteria
- ECOG performance status of 0, 1, or 2
- Life expectancy of at least 3 months
- Ability to read, understand, and sign informed consent form
You will not qualify if you...
- Currently participating or planning to participate in any other interventional clinical study
- Investigator considers patient unsuitable for this study
- Non-secretory myeloma
- Received antimyeloma therapy or high-dose corticosteroids within 2 weeks before treatment
- Received allogeneic stem cell transplant within 1 year or used immunosuppressive drugs within 1 month prior to enrollment
- Inadequate bone marrow reserve (low platelet or neutrophil counts)
- Clinically significant lung disease including COPD with FEV1 less than 50% or uncontrolled moderate/severe asthma
- Significant cardiac disease including recent myocardial infarction, unstable angina, heart failure class III-IV, severe arrhythmia, or QT interval over 470 ms
- Severe liver dysfunction unless related to myeloma
- Creatinine clearance less than 20 mL/min
- Known allergy to study drug components or severe hypersensitivity
- Serious uncontrolled medical conditions that may interfere with study participation
- HIV positive or active hepatitis B or C
- History of active cancer within past 5 years except certain skin or cervical cancers
- Unable to comply with study protocol due to substance abuse or psychological disorders
- Pregnant or breastfeeding females
- Peripheral neuritis grade 3 or higher
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bing Xu
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
Z
Zhijuan Lin, PhD
CONTACT
B
Bing Xu, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here